HIV 感染者的血脂异常与血脂管理。
Dyslipidemia and lipid management in HIV-infected patients.
机构信息
Department of Medicine, Harvard Medical School, Program in Nutritional Metabolism, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
出版信息
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
Abstract
PURPOSE OF REVIEW
Dyslipidemia is highly prevalent among patients living with chronic HIV infection and may confer increased risk of cardiovascular disease in this patient population. This review summarizes recent data investigating lipid abnormalities and its management in HIV-infected patients.
RECENT FINDINGS
Studies in the last year have evaluated the effects of various lipid-lowering therapies not previously investigated in the HIV patient population. Rosuvastatin is a potent statin that appears to be well tolerated and effective in HIV-infected patients with hypercholesterolemia.
SUMMARY
Dyslipidemia is common in HIV-infected individuals. Medical therapy of lipid disorders needs to take potential drug-drug interactions of lipid-lowering medications and antiretroviral agents into consideration.
摘要
目的综述
血脂异常在慢性 HIV 感染患者中非常普遍，可能会增加该患者人群患心血管疾病的风险。本综述总结了最近研究 HIV 感染患者中脂质异常及其管理的相关数据。
最近的发现
过去一年的研究评估了各种降脂治疗药物的作用，这些药物以前并未在 HIV 患者人群中进行过研究。瑞舒伐他汀是一种强效他汀类药物，似乎在患有高胆固醇血症的 HIV 感染患者中耐受性良好且有效。
总结
血脂异常在 HIV 感染者中很常见。治疗血脂异常的药物治疗需要考虑降脂药物和抗逆转录病毒药物之间潜在的药物相互作用。
相似文献
1
Dyslipidemia and lipid management in HIV-infected patients.HIV 感染者的血脂异常与血脂管理。
Curr Opin Endocrinol Diabetes Obes. 2011 Apr;18(2):144-7. doi: 10.1097/MED.0b013e328344556e.
2
Lipid management in patients who have HIV and are receiving HIV therapy.对感染艾滋病毒且正在接受抗逆转录病毒治疗的患者进行血脂管理。
Endocrinol Metab Clin North Am. 2009 Mar;38(1):207-22. doi: 10.1016/j.ecl.2008.11.009.
3
Clinical management considerations for dyslipidemia in HIV-infected individuals.HIV 感染者血脂异常的临床管理注意事项。
Postgrad Med. 2012 Jan;124(1):31-40. doi: 10.3810/pgm.2012.01.2515.
4
Fenofibrate in the treatment of dyslipidemia associated with HIV infection.非诺贝特治疗与 HIV 感染相关的血脂异常。
Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):995-1004. doi: 10.1517/17425255.2010.504715.
5
Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction.贝特类药物是现代调脂治疗不可或缺的部分：聚焦于致动脉粥样硬化性血脂异常和残余风险降低。
Cardiovasc Diabetol. 2012 Oct 11;11:125. doi: 10.1186/1475-2840-11-125.
6
Management of lipid disorders in patients living with HIV.HIV感染者血脂异常的管理。
J Clin Pharmacol. 2015 Sep;55(9):957-74. doi: 10.1002/jcph.473. Epub 2015 Jun 23.
7
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.感染HIV和未感染HIV的患者对新开具的降脂治疗的反应。
Ann Intern Med. 2009 Mar 3;150(5):301-13. doi: 10.7326/0003-4819-150-5-200903030-00006.
8
Lipid metabolism in treated HIV Infection.治疗后 HIV 感染的脂代谢。
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):429-42. doi: 10.1016/j.beem.2011.04.004.
9
Dyslipidemia in HIV-infected individuals.HIV 感染者的血脂异常。
Braz J Infect Dis. 2010 Nov-Dec;14(6):575-88. doi: 10.1016/s1413-8670(10)70115-x.
10
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.一种基于证据的多模式方法用于实现抗逆转录病毒相关血脂异常治疗中的血脂目标：病例报告及文献综述
Pharmacotherapy. 2008 Jul;28(7):932-8. doi: 10.1592/phco.28.7.932.
引用本文的文献
1
Pathogenesis of HIV-Associated Metabolic Syndrome and Clinical Management Recommendations.HIV 相关代谢综合征的发病机制及临床管理建议
Int J Gen Med. 2025 Sep 9;18:5213-5232. doi: 10.2147/IJGM.S528870. eCollection 2025.
2
Metabolic dysfunction-associated steatotic liver disease in people with HIV.HIV感染者中与代谢功能障碍相关的脂肪性肝病
Curr Opin HIV AIDS. 2025 Jul 1;20(4):350-358. doi: 10.1097/COH.0000000000000952. Epub 2025 May 21.
3
Addressing Cardiometabolic Challenges in HIV: Insights, Impact, and Best Practices for Optimal Management-A Narrative Review.应对HIV患者的心脏代谢挑战：最佳管理的见解、影响及最佳实践——一篇叙述性综述
Health Sci Rep. 2025 Apr 18;8(4):e70727. doi: 10.1002/hsr2.70727. eCollection 2025 Apr.
4
PVAT adipocyte: energizing, modulating, and structuring vascular function during normotensive and hypertensive states.内脏脂肪组织脂肪细胞：在正常血压和高血压状态下为血管功能供能、调节并构建血管功能
Am J Physiol Heart Circ Physiol. 2025 Jun 1;328(6):H1204-H1217. doi: 10.1152/ajpheart.00093.2025. Epub 2025 Apr 18.
5
Deciphering the Association: Critical HDL-C Levels and Their Impact on the Glycation Gap in People Living with HIV.解读关联：HIV感染者的临界高密度脂蛋白胆固醇水平及其对糖化间隙的影响
Int J Mol Sci. 2025 Jan 22;26(3):914. doi: 10.3390/ijms26030914.
6
HIV-Associated Hypertension: Risks, Mechanisms, and Knowledge Gaps.HIV 相关高血压：风险、机制和知识空白。
Circ Res. 2024 May 24;134(11):e150-e175. doi: 10.1161/CIRCRESAHA.124.323979. Epub 2024 May 23.
7
Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study.在 HIV-1 感染者中，转换为基于阿尼鲁韦的方案与继续基于依非韦伦的方案的疗效和血脂谱影响：来自真实世界、回顾性、多中心队列研究的 24 周结果。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0166823. doi: 10.1128/aac.01668-23. Epub 2024 Mar 14.
8
Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients.人类免疫缺陷病毒患者的体重增加与代谢综合征
Infect Chemother. 2022 Jun;54(2):220-235. doi: 10.3947/ic.2022.0061. Epub 2022 May 31.
9
Metabolic Consequences of Antiretroviral Therapy.抗逆转录病毒疗法的代谢后果
Curr HIV/AIDS Rep. 2022 Apr;19(2):141-153. doi: 10.1007/s11904-022-00600-6. Epub 2022 Mar 17.
10
Spectrum of Dyslipidemias in Treatment-Naïve Human Immunodeficiency Virus-Infected Patients Presenting to an HIV Clinic of a Tertiary Care Hospital.在一家三级护理医院的艾滋病诊所就诊的初治人类免疫缺陷病毒感染患者的血脂异常谱。
Cureus. 2022 Feb 7;14(2):e21972. doi: 10.7759/cureus.21972. eCollection 2022 Feb.
本文引用的文献
1
Drug-drug interactions between raltegravir and pravastatin in healthy volunteers.健康志愿者中雷迪帕韦与普伐他汀的药物相互作用。
J Acquir Immune Defic Syndr. 2010 Sep;55(1):82-6. doi: 10.1097/QAI.0b013e3181d9a354.
2
Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy.稳定抗反转录病毒治疗的 HIV 感染患者中，烟酸持续释放制剂对血管内皮功能的短期影响。
AIDS. 2010 Apr 24;24(7):1019-23. doi: 10.1097/QAD.0b013e3283383016.
3
Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men.冠状动脉计算机断层摄影血管造影术检测到的 HIV 感染男性亚临床冠状动脉粥样硬化的患病率增加。
AIDS. 2010 Jan 16;24(2):243-53. doi: 10.1097/QAD.0b013e328333ea9e.
4
Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial.在接受蛋白酶抑制剂治疗的血脂异常 HIV-1 感染患者中，瑞舒伐他汀与普伐他汀的比较：一项随机试验。
AIDS. 2010 Jan 2;24(1):77-83. doi: 10.1097/QAD.0b013e328331d2ab.
5
Lipoprotein particle subclasses, cardiovascular disease and HIV infection.脂蛋白颗粒亚类、心血管疾病与 HIV 感染。
Atherosclerosis. 2009 Dec;207(2):524-9. doi: 10.1016/j.atherosclerosis.2009.05.001. Epub 2009 May 13.
6
Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection.感染HIV和未感染HIV的患者对新开具的降脂治疗的反应。
Ann Intern Med. 2009 Mar 3;150(5):301-13. doi: 10.7326/0003-4819-150-5-200903030-00006.
7
Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy.依折麦布单药治疗可降低接受抗逆转录病毒联合治疗的HIV感染患者的低密度脂蛋白胆固醇水平。
Clin Infect Dis. 2008 Oct 15;47(8):1105-8. doi: 10.1086/592116.
8
Rosiglitazone increases small dense low-density lipoprotein concentration and decreases high-density lipoprotein particle size in HIV-infected patients.罗格列酮可增加HIV感染患者的小而密低密度脂蛋白浓度，并减小高密度脂蛋白颗粒大小。
AIDS. 2007 Nov 30;21(18):2543-6. doi: 10.1097/QAD.0b013e3282f25123.
9
Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.鱼油和非诺贝特用于接受抗逆转录病毒治疗的HIV感染受试者高甘油三酯血症的治疗：ACTG A5186研究结果
J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):459-66. doi: 10.1097/QAI.0b013e31815bace2.
10
Increased carotid intima media thickness and cardiac biomarkers in HIV infected children.HIV感染儿童的颈动脉内膜中层厚度增加及心脏生物标志物变化
AIDS. 2007 May 11;21(8):921-7. doi: 10.1097/QAD.0b013e328133f29c.
Zotero 插件